Total number of patients treated with specified drugs and of those treated number who had primary diagnosis of specified conditions

<table>
<thead>
<tr>
<th>Drug treated with</th>
<th>Dec 16 - Feb 17 (most recent fully coded 3 months)</th>
<th>For the following conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Follicular lymphoma</td>
<td>Diffuse Large B-cell lymphoma</td>
</tr>
<tr>
<td>MabThera IV (rituximab)</td>
<td>X71.5, X72.2</td>
<td>194</td>
</tr>
<tr>
<td>MabThera SC (rituximab)</td>
<td>X71.5, X72.3</td>
<td>255</td>
</tr>
<tr>
<td>Truxima (rituximab)</td>
<td>X71.3, X72.2</td>
<td>172</td>
</tr>
<tr>
<td>Gazyvaro (obinutuzumab)</td>
<td>X70.8, X72.9 Unknown Regimen</td>
<td>30</td>
</tr>
<tr>
<td>Imbruvica (ibrutinib)</td>
<td>X71.5, X73.1</td>
<td>173</td>
</tr>
<tr>
<td>Zydelig (idelalisib)</td>
<td>X70.8, X72.9 Unknown Regimen</td>
<td>30</td>
</tr>
<tr>
<td>Arzerra (ofatumumab)</td>
<td>loading dose X70.4, X721 monthly/ weekly dose X71.5, X72.1</td>
<td>224</td>
</tr>
</tbody>
</table>

*not treated with these drugs

Rituximab X92.1 | 357 | | | | | 160